| Title |
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, June 2016
|
| DOI | 10.1007/s40256-016-0172-5 |
| Pubmed ID | |
| Authors |
Remo Holanda de Mendonça Furtado, Robert Patrick Giugliano, Celia Maria Cassaro Strunz, Cyrillo Cavalheiro Filho, José Antonio Franchini Ramires, Roberto Kalil Filho, Pedro Alves Lemos Neto, Alexandre Costa Pereira, Tânia Rúbia Rocha, Beatriz Tonon Freire, Elbio Antonio D’Amico, José Carlos Nicolau |
| Abstract |
Proton-pump inhibitors (PPIs) are often prescribed to patients receiving dual antiplatelet therapy (DAPT). However, this class of medication, especially omeprazole, has been associated with a reduction in clopidogrel efficacy, leading many clinicians to substitute omeprazole with ranitidine. Our objective was to compare the antiplatelet effect of clopidogrel before and after the addition of omeprazole or ranitidine. We measured platelet aggregability at baseline and after 1 week of clopidogrel 75 mg daily. Subjects were then randomized in a double-blinded, double-dummy fashion to omeprazole 20 mg twice daily (bid) or ranitidine 150 mg bid. We repeated aggregability tests after 1 additional week, using VerifyNow P2Y12™ (Accumetrics; San Diego, CA, USA), depicting aggregability as percent inhibition of platelet aggregation (IPA). We enrolled 41 patients in the omeprazole group and 44 in the ranitidine group. IPA was significantly decreased after the addition of omeprazole to clopidogrel (from 26.3 ± 32.9 to 17.4 ± 33.1 %; p = 0.025), with no statistical significant changes observed in the ranitidine group (from 32.6 ± 28.9 to 30.1 ± 31.3 %; p = 0.310). The comparison of IPA in both groups at the end of the follow-up showed a trend toward significance (p = 0.07, 95 % confidence interval [CI] -1.19 to 26.59); after excluding homozygous patients for 2C19*2 genotype, the comparison of IPA between the groups reached statistical significance (32.7 ± 30.8 vs. 17.7 ± 33.4 %, respectively, for ranitidine and omeprazole groups; p = 0.04). Unlike omeprazole, ranitidine did not influence platelet aggregability response to clopidogrel. NCT01896557. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 8 | 62% |
| El Salvador | 1 | 8% |
| Unknown | 4 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 57 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 16% |
| Student > Master | 7 | 12% |
| Other | 6 | 10% |
| Student > Postgraduate | 4 | 7% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 11 | 19% |
| Unknown | 17 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 26% |
| Unspecified | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 20 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2017.
All research outputs
#4,183,857
of 25,373,627 outputs
Outputs from American Journal of Cardiovascular Drugs
#80
of 467 outputs
Outputs of similar age
#69,593
of 364,776 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#2
of 8 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 467 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,776 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.